CHICAGO, IL--(Marketwire - November 21, 2012) - More that 25,000 radiologists and clinicians from around the world are meeting this week in Chicago, Illinois for the annual Radiological Society of North America (RSNA) conference. Mirada Medical and collaborators are demonstrating the importance of quantitative assessment in imaging; specifically, how multi-modal imaging may influence quantitative reporting in oncology patients and the benefit of volumetric measurements in CT, MR, and PET/CT.
"We are showing how measurements can be made reproducible and consolidated across sub-specialties including CT, MR, PET/CT, and longitudinally," stated Dr Mark Gooding, head researcher for the program. "We are also demonstrating how volumetric measurements can enable clinicians to get a clearer picture of disease state and how it can be incorporated into a radiologist's workflow while maintaining efficiency," concluded Gooding.
The title of the educational presentation is Quantitative Reading in Multimodal Oncology Imaging. It was selected by the RSNA for inclusion in the Quantitative Imaging Reading Room (QIRR, exhibit 3013), a special educational section dedicated to quantitative imaging innovation. The study was conducted in collaboration with leading clinicians from The University of Arkansas for Medical Sciences (UAMS) utilizing Mirada Medical XD3 advanced image analysis software tools. Dr Marcus Keller, M.D, of UAMS, will be present in the QIRR exhibit 12:30-1:30 PM daily for a "Meet the Experts" session to discuss the clinical findings of the study. Dr. Etienne von Lavante, D.Phil., of Mirada Medical, will represent the technology aspects.
Mirada Medical will also be demonstrating their latest range of advanced image review and analysis software capabilities in the South technical exhibit hall, booth 8744, at McCormick Place.
About Mirada Medical Ltd
Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada's products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumor board and elsewhere.
The company specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. Mirada's advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world's leading healthcare companies.
Mirada Medical was originally spun out of the University of Oxford. The company's technologies and products continue to be developed by their team of specialists, engineers and world-renowned scientists at Mirada's world headquarters in Oxford, England.
Mirada Medical, RTx, Casemeeting, Caseaccess and XD3 are all trademarks of Mirada Medical Ltd.